Cure CMD (Congenital Muscular Dystrophy)

Administers Cure CMD Congenital Muscular Dystrophy in United States, delivering updates and pathways through curecmd.org.

Cure CMD is a US-based patient-advocacy foundation founded in 2008 by three parents of children with congenital muscular dystrophy. It funds international research into CMD and has distributed about $4 million in research grants over more than 15 years.

Its program targets five main CMD subtypes: Collagen 6 disorders such as Ullrich and Bethlem, LAMA2-related disease, congenital dystroglycanopathies, congenital laminopathy, and SELENON-related myopathy. The foundation supports natural history studies, biomarker discovery, gene therapy development, disease modeling, drug screening, and translational therapies through a grant route capped at $100,000.

The current research grant cycle is between rounds, with the last open request for applications in 2022. That makes the organization a specialized disease foundation with periodic research competitions rather than a continuously open funder, and its best-fit applicants are teams with preclinical data and a clear route from molecular biology to patient-facing translation. Its cadence is periodic, not annual, so applicants need to watch for the next call rather than expect a standing deadline.